Louise Wright.jpg (1)

Action for Pulmonary Fibrosis Appoints New CEO

Friday, December 21, 2018

Action for Pulmonary Fibrosis – the campaigning voice and UK charity for patients with this devastating lung disease – announced this month the appointment of Louise Wright as their CEO. 


Louise has over twenty years’ experience of leading growth in the charity sector.  She started working on award-winning fundraising campaigns for the NSPCC and Shelter before becoming CEO at Back Up, a national charity transforming the lives of people affected by paralysis. 


Louise is passionate about the charity sector.  She is an active volunteer with health and disability charities, sharing her expertise on governance, fundraising and communications to improve impact. She is a founder member of Vitality, a charity working in developing countries that has improved the lives and life expectancy of hundreds of families affected by paralysis in Bangladesh.


Louise Wright, says:

“I am thrilled to be starting as CEO at Action for Pulmonary Fibrosis.  I’m delighted to be able to bring a wealth of experience to this excellent charity and help it realize its ambitions of raising awareness of this terrible disease, improving the care people receive once diagnosed and accelerating the reality of finding a cure. Joining the exceptional team that’s already in place is a real privilege.”


Steve Jones, Chair of Action for Pulmonary Fibrosis, says:

“We are absolutely delighted to welcome Louise Wright as CEO. We have ambitious development plans for the coming years. Louise will drive our commitment to achieve our goal of supporting patients with pulmonary fibrosis achieve the best possible outcomes.”


Action for Pulmonary Fibrosis was set up in 2013 by a group of patients, family members, carers and medical specialists to provide support for patients diagnosed with the devastating terminal lung disease pulmonary fibrosis. Idiopathic Pulmonary Fibrosis (IPF), the most common form of the disease, kills 6,000 people each year in the UK – the same as die from leukaemia  – but it doesn’t have a high profile and is poorly understood.